Ranolazine
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
End-stage Renal Disease
Conditions
End-stage Renal Disease, Cardiovascular Disease
Trial Timeline
Oct 1, 2011 → Mar 1, 2013
NCT ID
NCT01435174About Ranolazine
Ranolazine is a approved stage product being developed by Gilead Sciences for End-stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01435174. Target conditions include End-stage Renal Disease, Cardiovascular Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02360397 | Phase 2 | Completed |
| NCT02251457 | Phase 1 | Completed |
| NCT01721967 | Approved | Completed |
| NCT01705509 | Pre-clinical | Terminated |
| NCT01804543 | Pre-clinical | UNKNOWN |
| NCT01435174 | Approved | Completed |
| NCT02133352 | Approved | Completed |
| NCT01334203 | Approved | Withdrawn |
| NCT01304095 | Approved | UNKNOWN |
| NCT01174173 | Phase 3 | Completed |
| NCT01163734 | Phase 2 | Completed |
| NCT00644332 | Approved | Completed |
| NCT00091429 | Phase 3 | Completed |
Competing Products
20 competing products in End-stage Renal Disease